| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71(3)：209-249.
|
| [2] |
Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer[J]. Cancer Cell，2020，37(4)：496-513.
|
| [3] |
Gu G, Dustin D, Fuqua SA.Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment[J]. Curr Opin Pharmacol，2016，31：97-103.
|
| [4] |
Nedeljkovic′ M, Damjanovic′ A. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge[J]. Cells，2019，8(9)：957.
|
| [5] |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials[J]. Lancet，2019，393(10 179)：1440-1452.
|
| [6] |
Charpin C, Vielh P, Duffaud F, et al.Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators[J]. J Natl Cancer Inst，1994，86(20)：1539-1545.
|
| [7] |
Kubota T, Furukawa T, Tanino H, et al.Resistant mechanisms of anthracyclines--pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues[J]. Breast Cancer，2001，8(4)：333-338.
|
| [8] |
Paget S. The distribution of secondary growths in cancer of the breast. 1889[J]. Cancer Metastasis Rev，1989，8(2)：98-101.
|
| [9] |
Sun Y. Tumor microenvironment and cancer therapy resistance [J]. Cancer Lett，2016，380(1)：205-215.
|
| [10] |
Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents. xiii. on the criteria and kinetics associated with " curability" of experimental leukemia[J]. Cancer Chemother Rep，1964，35：1-111.
|
| [11] |
Norton L. Cancer log-kill revisited[J]. Am Soc Clin Oncol Educ Book，2014：3-7.
|
| [12] |
Norton L, Simon R, Brereton HD, et al. Predicting the course of Gompertzian growth[J]. Nature，1976，264(5586)：542-545.
|
| [13] |
McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future[J]. Cell，2017，168(4)：613-628.
|
| [14] |
Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies[J]. Nat Rev Clin Oncol，2018，15(2)：81-94.
|
| [15] |
Tep J, Videmann B, Mazallon M, et al. Transepithelial transport of fusariotoxin nivalenol: mediation of secretion by ABC transporters[J]. Toxicol Lett，2007，170(3)：248-258.
|
| [16] |
Gilbert L, Elwood LJ, Merino M, et al. A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer[J]. J Clin Oncol, 1993，11(1)：49-58.
|
| [17] |
Minisini AM, Di Loreto C, Mansutti M, et al.Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer[J]. Cancer Lett，2005，224(1)：133-139.
|
| [18] |
Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy[J]. Annu Rev Immunol，2013，31：51-72.
|
| [19] |
Koual M, Tomkiewicz C, Cano-Sancho G, et al. Environmental chemicals, breast cancer progression and drug resistance[J]．Environ Health，2020，19(1)：117.
|
| [20] |
Sato H, Niimi A, Yasuhara T, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells[J]. Nat Commun，2017，8(1)：1751.
|
| [21] |
Cui L, Huang J, Zhan Y, et al. Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy[J]. Life Sci，2021，276：119 392.
|
| [22] |
Rivera E, Smith RE Jr. Trends in recommendations of myelosuppressive chemotherapy for the treatment of breast cancer: evolution of the national comprehensive cancer network guidelines and the cooperative group studies[J]. Clin Breast Cancer，2006，7(1)：33-41.
|
| [23] |
Pellegrino B, Hlavata Z, Migali C, et al.Luminal breast cancer: risk of recurrence and tumor-associated immune suppression[J]. Mol Diagn Ther，2021，25(4)：409-424.
|
| [24] |
Park YH, Lal S, Lee JE, et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome[J]. Nat Commun，2020，11(1)：6175.
|
| [25] |
Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer[J]. Lancet Oncol，2014，15(2)：e58-e68.
|
| [26] |
Winer EP, Lipatov O, Im SA, et al.Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial[J]. Lancet Oncol，2021，22(4)：499-511.
|
| [27] |
Hoffmann L. A study comparing atezolizumab (anti PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer (IMpassion030)[EB/OL]．[2022-03-21].
URL
|
| [28] |
Pierfranco C. Adjuvant treatment for high-risk triple negative breast cancer patients with the anti-PD-l1 antibody avelumab (A-Brave)[EB/OL]．[2022-03-21].
URL
|
| [29] |
Lajos P. Testing MK-3475 (pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer[EB/OL]．[2022-03-21].
URL
|
| [30] |
Bachelot T, Filleron T, Bieche I, et al. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial[J]. Nat Med，2021，27(2)：250-255.
|
| [31] |
Sarah S. Phase II multicenter study of durvalumab and olaparib in platinum treated advanced triple negative breast cancer (DORA)[EB/OL]．[2022-03-21].
URL
|
| [32] |
Merck S, Dohme C. Study of olaparib plus pembrolizumab versus chemotherapy plus pembrolizumab after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC) (MK-7339-009/KEYLYNK-009) [EB/OL]．[2022-03-21].
URL
|
| [33] |
Merck S, Dohme C. Safety and efficacy study of pembrolizumab (MK-3475) in combination with chemotherapy as neoadjuvant treatment for participants with triple negative breast cancer (TNBC) (MK-3475-173/KEYNOTE-173) [EB/OL]．[2022-03-21].
URL
|
| [34] |
Nanda R, Liu MC, Yau C, et al.Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial[J]. JAMA Oncol，2020，6(5)：676-684.
|
| [35] |
Ott PA, Bang YJ, Piha-Paul SA, et al.T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028[J]. J Clin Oncol，2019，37(4)：318-327.
|
| [36] |
Tolaney SM, Barroso-Sousa R, Keenan T, et al. Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor-positive, erbb2-negative metastatic breast cancer: a randomized clinical trial[J]. JAMA Oncol, 2020，6(10)：1598-1605.
|
| [37] |
Clinton Y. Pembrolizumab in treating patients with hormone receptor positive, localized inflammatory breast cancer who are receiving hormone therapy and did not achieve a pathological complete response to chemotherapy[EB/OL]．[2022-03-21].
URL
|
| [38] |
Shaheenah D. Pembrolizumab and tamoxifen among women with advanced hormone receptor positive breast cancer and Esr1 mutation (Pembro) [EB/OL]．[2022-03-21].
URL
|
| [39] |
Emens LA, Esteva FJ, Beresford M, et al.Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial[J]. Lancet Oncol，2020，21(10)：1283-1295.
|
| [40] |
Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion 031): a randomised, double-blind, phase 3 trial[J]. Lancet，2020，396(10 257)：1090-1100.
|
| [41] |
Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts[J]. Nat Rev Drug Discov，2019，18(2)：99-115.
|
| [42] |
Cox TR. The matrix in cancer[J]. Nat Rev Cancer，2021，21(4)：217-238.
|
| [43] |
Lovitt CJ, Shelper TB, Avery VM. Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins[J]. BMC Cancer，2018，18(1)：41.
|
| [44] |
Kim HW, Park JE, Baek M, et al. Matrix metalloproteinase-1 (mmp1) upregulation through promoter hypomethylation enhances tamoxifen resistance in breast cancer[J]. Cancers (Basel)，2022，14(5)：1232.
|
| [45] |
Robertson C. The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking[J]. Exp Cell Res，2016，343(1)：73-81.
|
| [46] |
Qin X, Lv X, Li P, et al.Matrix stiffness modulates ILK-mediated YAP activation to control the drug resistance of breast cancer cells[J]. Biochim Biophys Acta Mol Basis Dis，2020，1866(3)：165 625.
|
| [47] |
Gao H, Tian Q, Zhu L, et al. 3D extracellular matrix regulates the activity of T cells and cancer associated fibroblasts in breast cancer[J]. Front Oncol，2021，11：764 204.
|
| [48] |
Zhang Y, Sun T, Jiang C. Biomacromolecules as carriers in drug delivery and tissue engineering[J]. Acta Pharm Sin B，2018，8(1)：34-50.
|
| [49] |
Deligne C, Midwood KS. Macrophages and extracellular matrix in breast cancer: partners in crime or protective allies? [J]. Front Oncol，2021，11：620 773.
|
| [50] |
Mpekris F, Panagi M, Voutouri C, et al.Normalizing the microenvironment overcomes vessel compression and resistance to nano-immunotherapy in breast cancer lung metastasis[J]. Adv Sci (Weinh)，2020，8(3)：2 001 917.
|
| [51] |
Ramadan WS, Zaher DM, Altaie AM, et al. Potential therapeutic strategies for lung and breast cancers through understanding the anti-angiogenesis resistance mechanisms[J]. Int J Mol Sci，2020，21(2)：565.
|
| [52] |
Trédan O, Lacroix-Triki M, Guiu S, et al. Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model[J]. Target Oncol，2015，10(2)：189-198.
|
| [53] |
Li Q, Wang Y, Jia W, et al. Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade[J]. Clin Cancer Res，2020，26(7)：1712-1724.
|
| [54] |
Iyengar NM, Gucalp A, Dannenberg AJ, et al. Obesity and cancer mechanisms: tumor microenvironment and inflammation[J]. J Clin Oncol，2016，34(35)：4270-4276.
|
| [55] |
Wang T, Fahrmann JF, Lee H, et al. JAK/STAT3-regulated fatty acid β-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance[J]. Cell Metab, 2018，27(1)：136-150.
|
| [56] |
Hoy AJ, Balaban S, Saunders DN. Adipocyte-tumor cell metabolic crosstalk in breast cancer[J]. Trends Mol Med，2017，23(5)：381-392.
|
| [57] |
Choi J, Cha YJ, Koo JS. Adipocyte biology in breast cancer: From silent bystander to active facilitator[J]. Prog Lipid Res，2018，69：11-20.
|
| [58] |
Incio J, Ligibel JA, McManus DT, et al.Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2[J]. Sci Transl Med, 2018，10(432)：eaag0945.
|